Diabetes Therapy

Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-Analysis

By Roya Ghafoury, Mobin Naghshbandi, Mojtaba Malek, Mohammad E. Khamseh

Fig. 1. PRISMA flow diagram of the study selection. — Fig. 1. PRISMA flow diagram of the study selection.PRISMA flow diagram of the study selection.Ghafoury et al.

Meta-analysisInterventions

Preregistered CRD420261320374, declared no competing interests

The paper

Roya Ghafoury, Mobin Naghshbandi, Mojtaba Malek, Mohammad E. Khamseh

Iran University of Medical Sciences

Diabetes Therapy, 1 Sep 2026

doi.org/10.1007/s13300-026-01911-2 PubMed 42678648

Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Cardiology and Therapy4 Oct 2026
Low-carb telemedicine links to fewer cardiovascular events
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes